2026-08-23T19:36:28Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1324882026-02-18T00:52:40Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Aladro, Yolandra author Terrero, Rodrigo author Cerezo García, Marta author Ginestal, Rocardo author Ayuso, Lucía author Meca-Lallana, Virginia author Millán, Jorge author Borrego, Laura author Martinez-Ginés, Marisa author Rubio, Luisa author De Andrés, Clara author Miralles, Ambrosio author Guijarro, Cristina author Rodríguez-García, Elena author García-Dominguez, José Manuel author Muñoz-Fernández, Carmen author López de Silanes, Carlos author Gómez, Mayra author Thuissard, Israel author Cerdán, María author Palmí, Itziar author Díaz-Garzón, Luis Felipe author Meca-Lallana, José author 2016-06 Objective: To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. Methods: Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. Results: The overall anti-JCV seroprevalence was 55.3% (51.6–58.9), similar across regions (p = 0.073). It increased with age (p b 0.000) and when STRATIFY-2 was used (60.5%, p = 0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. Conclusions: JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions. Aladro, Y., Terrero, R., Cerezo, M., Ginestal, R., Ayuso, L., Meca-Lallana, V., Millán, J., Borrego, L., Martinez-Ginés, M., Rubio, L., De Andrés, C., Miralles, A., Guijarro, C., Rodríguez-García, E., García-Dominguez, J. M., Muñoz-Fernández, C., López De Silanes, C., Gómez, M., Thuissard, I., et al. (2016). Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort JC virus seroprevalence in Spain. Journal of the Neurological Sciences, 365, 16-21. https://doi.org/10.1016/J.JNS.2016.03.050 0022-510X 10.1016/j.jns.2016.03.050 https://hdl.handle.net/20.500.14352/132488 1878-5883 https://doi.org/10.1016/j.jns.2016.03.050 27206867 https://produccioncientifica.ucm.es/documentos/6038dad985382a6b3d7bb6db https://pubmed.ncbi.nlm.nih.gov/27206867/ https://www.webofscience.com/wos/woscc/full-record/WOS:000377313600005 https://www.scopus.com/pages/publications/84962786594 https://www.sciencedirect.com/science/article/pii/S0022510X16301812?via%3Dihub http://hdl.handle.net/11268/8391 Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain